Medicine Consent Notices




1 APRIL 2004

NEW ZEALAND GAZETTE, No. 39

981

Product:
Lipitor

Active Ingredient:
Atorvastatin calcium 86.76mg equivalent to 80mg atorvastatin

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Pfizer New Zealand Limited

Manufacturer:
Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico

Product:
Seretide Accuhaler

Active Ingredients:
Fluticasone propionate 100µg
Salmeterol xinafoate 72.5µg equivalent to 50µg of salmeterol base

Dosage Form:
Powder for inhalation

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Operations UK Limited, Ware, Hertfordshire, United Kingdom
Glaxo Wellcome Production, Evreux, France

Product:
Seretide Accuhaler

Active Ingredients:
Fluticasone propionate 250µg
Salmeterol xinafoate 72.5µg equivalent to 50µg of salmeterol base

Dosage Form:
Powder for inhalation

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Operations UK Limited, Ware, Hertfordshire, United Kingdom
Glaxo Wellcome Production, Evreux, France

Product:
Seretide Accuhaler

Active Ingredients:
Fluticasone propionate 500µg
Salmeterol xinafoate 72.5µg equivalent to 50µg of salmeterol base

Dosage Form:
Powder for inhalation

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Operations UK Limited, Ware, Hertfordshire, United Kingdom
Glaxo Wellcome Production, Evreux, France

Product:
Seretide

Active Ingredients:
Fluticasone propionate 20mg equivalent to 125µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol

Dosage Form:
Aerosol inhaler, metered dose

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France

Product:
Seretide

Active Ingredients:
Fluticasone propionate 40mg equivalent to 250µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol

Dosage Form:
Aerosol inhaler, metered dose

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France

Product:
Seretide

Active Ingredients:
Fluticasone propionate 8mg equivalent to 50µg/dose
Salmeterol xinafoate 5.8mg equivalent to 25µg/dose salmeterol

Dosage Form:
Aerosol inhaler, metered dose

New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited

Manufacturers:
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France

Dated this 29th day of March 2004.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).

go2178



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2004, No 39


Gazette.govt.nz PDF NZ Gazette 2004, No 39





✨ LLM interpretation of page content

🏥 Consent to the Distribution of Changed Medicines (continued from previous page)

🏥 Health & Social Welfare
29 March 2004
Medicines, Consent, Changed, Lipitor, Seretide, Atorvastatin, Fluticasone, Salmeterol
  • DON MATHESON, Deputy Director-General, Public Health